Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of “Buy” from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have earned a consensus rating of “Buy” from the nine research firms that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $80.67.

Separately, Zacks Investment Research upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Thursday.

In other news, VP Mary Beth Fritz sold 5,759 shares of the firm’s stock in a transaction on Friday, March 5th. The stock was sold at an average price of $42.80, for a total transaction of $246,485.20. Following the completion of the transaction, the vice president now directly owns 16,499 shares in the company, valued at $706,157.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.20% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Veriti Management LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at $135,000. XTX Markets LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at $206,000. GSA Capital Partners LLP acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at $220,000. SG Americas Securities LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at $222,000. Finally, Burney Co. acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth about $230,000.

Shares of PBH stock traded down $0.05 during trading hours on Thursday, reaching $43.43. The company had a trading volume of 3,468 shares, compared to its average volume of 594,981. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.14 and a current ratio of 1.98. The stock has a fifty day moving average of $43.92 and a 200-day moving average of $38.53. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of 13.47, a PEG ratio of 2.96 and a beta of 0.76. Prestige Consumer Healthcare has a 12-month low of $32.19 and a 12-month high of $47.98.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Wednesday, February 3rd. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.04. The business had revenue of $238.80 million during the quarter, compared to analyst estimates of $231.55 million. Prestige Consumer Healthcare had a return on equity of 13.76% and a net margin of 17.03%. The business’s revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.81 earnings per share. On average, analysts forecast that Prestige Consumer Healthcare will post 3.18 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Featured Article: Oversold

Analyst Recommendations for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.